Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.

Oncotarget - 1 Nov 2016

Ozaki Toshinori, Nakamura Mizuyo, Ogata Takehiro, Sang Meijie, Yoda Hiroyuki, Hiraoka Kiriko, Sang Meixiang, Shimozato Osamu

Abstract excerpt

Recently, we have described that siRNA-mediated silencing of runt-related transcription factor 2 (RUNX2) improves anti-cancer drug gemcitabine (GEM) sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the augmentation of p53 family TAp63-dependent cell death pathway. In this manuscript, we have extended our study to p53-mutated human pancreatic cancer Panc-1 cells. According to our present...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Cell Cycle Checkpoints

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Core Binding Factor Alpha 1 Subunit

Share to Deoxycytidine

Share to Drug Resistance, Neoplasm

Share to Gemcitabine

Share to Genes, p53

Share to Pancreatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 27713122
DOI: 10.18632/oncotarget.12433
PMCID: PMC5342134

Genes

GEM
RUNX2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.PMID 27713122Read ↗

Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.Semantic proximity Read ↗

Impact of RUNX2 gene silencing on the gemcitabine sensitivity of p53‑mutated pancreatic cancer MiaPaCa‑2 spheres.Semantic proximity Read ↗

Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63.Semantic proximity Read ↗

TP53 Gene Therapy as a Potential Treatment for Patients with COVID-19Semantic proximity Read ↗

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.Semantic proximity Read ↗

Drug-Induced p53 Activation Limits Pancreatic Cancer InitiationSemantic proximity Read ↗

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract CancersSemantic proximity Read ↗

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.Semantic proximity Read ↗

The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancersSemantic proximity Read ↗

NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancerSemantic proximity Read ↗

The p53-homologue p63 may promote thyroid cancer progression.Semantic proximity Read ↗

Phospho-ΔNp63α-dependent microRNAs modulate chemoresistance of squamous cell carcinoma cells to cisplatin: at the crossroads of cell life and death.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.